PolyPid Announces Publication of Preclinical Data Further Supporting the Good Safety Profile of D-PLEX and PLEX Technology Platform
Portfolio Pulse from Benzinga Newsdesk
PolyPid Ltd. (NASDAQ:PYPD) has published positive preclinical results demonstrating the safety profile of D-PLEX100 and the PLEX technology platform in juvenile animals. The safety and toxicokinetics of D-PLEX100 were tested in juvenile swine for a period of nine months with no treatment-related adverse events observed. PolyPid's ongoing Phase 3 SHIELD II trial of D-PLEX100 for the prevention of surgical site infections is currently recruiting patients.
October 04, 2023 | 11:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
PolyPid Ltd. has published positive preclinical results for D-PLEX100 and PLEX technology platform, indicating a good safety profile. This could potentially boost investor confidence in the company's ongoing Phase 3 trial.
Positive preclinical results are a good sign for the potential success of a drug. This could increase investor confidence in the company's ongoing Phase 3 trial, potentially leading to an increase in the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100